Teva Pharmaceutical Industries Ltd. has completed its previously announced acquisition of Representaciones e Investigaciones Médicas, S.A. de C.V. (Rimsa), a pharmaceutical manufacturing and distribution company in Mexico, together with a portfolio of products and companies, intellectual property, assets and pharmaceutical patents in Latin America and Europe in a set of transactions for an aggregate of $2.3 billion.

“This acquisition delivers on our strategy of increasing our presence in key emerging markets and offers a platform for further growth in the region. Rimsa will provide Teva with a strong brand, unique portfolio of patent-protected products, a promising pipeline and significant relationships with patients, physicians and other healthcare providers,” said Erez Vigodman, President and CEO of Teva, in a company statement.

Rimsa has had annual growth, year-over-year of 10.6% since 2011. The company has a portfolio of patent-protected products, including fixed-dose combination products.

Source: Teva Pharmaceutical Industries